Europe’s CHMP Supports Carvykti T-cell Therapy Approval in EU

Carvykti (ciltacabtagene autoleucel; cilta-cel) has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), for eligible adults with relapsed and refractory multiple myeloma. The CAR T-cell therapy will be available for patients who have received at least three prior lines of treatment, including a CD38 inhibitor, a proteasome inhibitor, and an immunomodulatory agent, and whose disease progressed on the most recent…

You must be logged in to read/download the full post.